Abstract
Immune checkpoint inhibition is a new and promising therapy approved for the treatment of various malignancies. Pembrolizumab is a potent tumour suppressor that acts by upregulating the immune system to recognise cancer cells, which may result in disrupted self-tolerance. We describe a case of seronegative ocular myasthenia gravis after treatment with pembrolizumab for metastatic melanoma. Her bilateral ptosis was refractory to conventional treatment, and she remains functionally blind as a result. As the availability and use of immunotherapy continues to rise, awareness of its immune-related adverse effects (irAEs) is crucial for clinicians.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
